Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Stevenage’s biotech dream is in jeopardy after GSK exodus
2+ hour, 2+ min ago (11+ words) The Times...
Spatial biology for drug target discovery
10+ hour, 42+ min ago (566+ words) The same cell can look like a different target depending on whether it is studied alone or in place. Two consequences follow directly from that loss, and both change how a target discovery team should read single-cell data. Validation is…...
LifeMine Therapeutics Raises $263 Million to Develop Fungi-Derived Transplant Drug
13+ hour, 3+ min ago (450+ words) MycoStories LifeMine Therapeutics has closed $263 million in financing to accelerate clinical trials of LIFE-001, a novel immunosuppressant drug discovered through fungal genomics. LIFE-001 works by directly blocking calcineurin activation without relying on immunophilin proteins, the mechanism responsible for the kidney,…...
Harell Data Debuts With $15M To Change Incentives, Speed Up AI Drug Discovery - TimmermanReport.com
6+ hour, 31+ min ago (525+ words) The Protein Data Bank was the unsung hero that made AlphaFold possible. For decades, the structural biologists, biochemists and others who put carefully curated protein structures in the public domain laid down the conditions for AI to eventually do something…...
Schrödinger-BMS collaboration centers on Bunsen for trillion-scale computational drug discovery
10+ hour, 10+ min ago (251+ words) Drug Discovery and Development By Brian Buntz | August 17, 2026 BMS has been “a customer of ours forever,” said Pat Lorton, Schrödinger’s chief technology officer and chief operating officer. The latest agreement has the two companies working together to develop new functionality…...
Register: From Facility to Delivery: Solving the Complex Science of ADC Linker-Payload Synthesis
9+ hour, 4+ min ago (183+ words) In this webinar, experts from SK pharmteco's European and North American sites will share practical experience addressing these challenges across the linker-payload development lifecycle—from facility and containment strategy through process and analytical development, scale-up, cleaning, and final product release....
Beyond the Numbers: How Specialization Is Redrawing the Global Nanotechnology Innovation Map | STATNANO
20+ hour, 42+ min ago (486+ words) This analytical report, jointly published by NCNST and NIISA, maps the global landscape of nanotechnology innovation by examining 1.07 million patents filed worldwide between 2000 and 2025. Its key finding is China’s statistical dominance, holding roughly 43% of the world’s patents, a substantial lead…...
Europe’s missing biotech bridge: Why IP ownership matters more than capital access
5+ hour, 22+ min ago (108+ words) Life Sciences IP Review - Europe’s missing biotech bridge: Why IP ownership matters more than capital access Europe’s biotechnology challenge is not only whether it can fund innovation. It is whether it can continue to originate and control the foundational IP…...
Fidji Simo says she believes AI can 'cure all diseases,' agreeing with Anthropic CEO Dario Amodei
4+ hour, 57+ min ago (410+ words) Fidji Simo, the former OpenAI executive who cofounded the biomedical startup ChronicleBio, said she believes AI can eventually cure all diseases, but smarter models alone won't get us there. In an X post on Monday, Simo responded to Anthropic CEO…...
Anthropic CEO claims AI could cure most diseases in 5-10 years
12+ hour, 19+ min ago (230+ words) Dario Amodei doubles down on his boldest prediction yet, even as he concedes the AI industry hasn't delivered on its biotech promises so far Dario Amodei wants you to believe that artificial intelligence will cure most human diseases within the…...